Radiotherapy for pathological stage Ia and IIa (Upper) Hodgkin's disease
| ISRCTN | ISRCTN98387311 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN98387311 |
| Protocol serial number | HD1-82 |
| Sponsor | Cancer Research UK (CRUK) (UK) |
| Funder | Cancer Research UK |
- Submission date
- 01/07/2001
- Registration date
- 01/07/2001
- Last edited
- 01/02/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Non randomised trial |
| Secondary study design | Non randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Lymphoma (Hodgkin's) |
| Intervention | This is a non randomised study, patients are grouped according to site and stage of disease: 1. Group A: Patients with pathological stage Ia (neck), IIa (neck) and Ia (axilla) are assigned to local field radiotherapy. Patients with neck disease receive 30 Gy midline in sixteen fractions over 3 weeks followed by an additional 5 Gy to the site of palpable disease. Patients with axillary disease receive 35 Gy midline in sixteen fractions over 3 weeks. 2. Group B: Patients with pathological stage Ia (supraclavicular), IIa (all sites except neck) are assigned to mantle radiotherapy. Patients receive a dose of 35 Gy mid line in twenty fractions over 4 weeks followed by an additional 6 Gy to the anterior mediastinum. |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 31/12/2001 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | |
| Key inclusion criteria | 1. Pathological stage Ia and IIa (upper) Hodgkin's disease 2. Aged 15 to 65 years |
| Key exclusion criteria | Patients with mediastinal disease will not in general be eligible for local radiotherapy alone |
| Date of first enrolment | 01/01/1998 |
| Date of final enrolment | 31/12/2001 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/02/2005 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
